| Literature DB >> 31542260 |
Young-Man Kwon1, Youri Lee1, Ki Hye Kim1, Yu Jin Jung1, Zhuo Li1, Subbiah Jeeva1, Sujin Lee2, Martin L Moore3, Sang-Moo Kang4.
Abstract
Pre-fusion stabilizing mutations (DS-Cav1) in soluble fusion (F) proteins of human respiratory syncytial virus (RSV) were previously reported. Here we investigated the antigenic and immunogenic properties of pre-fusion like RSV F proteins on enveloped virus-like particles (VLP). Additional mutations were introduced to DS-Cav1 (F-dcmTM VLP); fusion peptide deletion and cleavage mutation site 1 (F1d-dcmTM VLP) or both sites (F12d-dcmTM VLP). F1d-dcmTM VLP and F12d-dcmTM VLP displayed higher reactivity against pre-fusion specific site Ø and antigenic site I and II specific monoclonal antibodies, compared to F-dcmTM VLP with DS-Cav1 only. Mice immunized with F1d-dcmTM VLP and F12d-dcmTM VLP induced higher levels of DS-Cav1 pre-fusion specific IgG antibodies, RSV neutralizing activity titers, and effective lung viral clearance after challenge. These results suggest that cleavage site mutations and fusion peptide deletion in addition to DS-Cav1 mutations have contributed to structural stabilization of pre-fusion like F conformation on enveloped VLP, capable of inducing high levels of pre-fusion F specific and RSV neutralizing antibodies.Entities:
Keywords: P27; Post-fusion transition; Prefusion; RSV; RSV F protein; VLP
Year: 2019 PMID: 31542260 PMCID: PMC6893914 DOI: 10.1016/j.vaccine.2019.09.041
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641